Your session is about to expire
← Back to Search
GM T Cell Therapy Long-Term Follow-Up for Cancer
Pamplona, Spain
Phase 2 & 3
Recruiting
Research Sponsored by Celgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored or Celgene alliance partner-sponsored study, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 15 years
Awards & highlights
No Placebo-Only Group
Summary
This trial will follow up on participants who received gene-modified T cell therapy in a previous study to see if the therapy is safe and effective in the long term.
Who is the study for?
This trial is for pediatric and adult patients who have previously received gene-modified (GM) T cell therapy in a Celgene sponsored or alliance partner study. Participants must have completed or discontinued the prior treatment protocol and be willing to sign an informed consent form.
What is being tested?
The study focuses on long-term follow-up of safety and efficacy for those who underwent GM T cell therapy. It's designed to monitor participants after they've finished their initial treatment, tracking any long-term effects.
What are the potential side effects?
Since this is a follow-up study, it will observe side effects from previous GM T cell therapy which may include immune reactions, infusion-related symptoms, and potential late-onset complications.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I've had a gene-modified T-cell infusion in a past Celgene study and completed the follow-up.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 15 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 15 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
B-Lymphocytes
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Participants exposed to Gene-modified (GM) T cell therapyExperimental Treatment1 Intervention
Find a Location
Closest Location:Local Institution - 01060· Seattle, WA
Who is running the clinical trial?
CelgeneLead Sponsor
645 Previous Clinical Trials
129,867 Total Patients Enrolled
1 Trials studying Tumors
107 Patients Enrolled for Tumors
Claudia Schusterbauer, MDStudy DirectorCelgene Corporation
3 Previous Clinical Trials
146 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,582 Previous Clinical Trials
3,388,284 Total Patients Enrolled
8 Trials studying Tumors
422 Patients Enrolled for Tumors
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- This criterion does not apply to me.I've had a gene-modified T-cell infusion in a past Celgene study and completed the follow-up.
Research Study Groups:
This trial has the following groups:- Group 1: Participants exposed to Gene-modified (GM) T cell therapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.